Company intelligence / Profile preview

cTRL Therapeutics

Chicago, Illinois, United Statesctrl-tx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

cTRL Therapeutics has developed a proprietary platform, IsoQore™, that enables the non-invasive extraction and expansion of rare, potent circulating T cells from blood. Their lead product candidate, cTRL‑001, aims to provide an outpatient-ready cell therapy solution for solid tumors. The company’s approach avoids the need for surgical removal of tumor tissue and seeks to overcome challenges faced by current cell therapies in solid cancers. As of late 2024/early 2025, their lead program remains preclinical with first-in-human trials anticipated in 2025[1][2][6].

Therapeutic areas: Oncology
Modalities: Cell therapy (autologous cell therapies using circulating tumor-reactive lymphocytes)
Industry: Biotech

Drug pipeline

1 asset

cTRL-001

Preclinical

Partnerships

FACIT (investment partner)Princess Margaret Cancer Centre & University Health Network/University of Toronto (academic collaborations)[2][6].

Beyond the preview

Go deeper on cTRL Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cTRL Therapeutics.